

Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, HRP

RRID:AB_429693

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# 31413, RRID:AB_429693

Antibody Information

URL: http://antibodyregistry.org/AB_429693

Proper Citation: Thermo Fisher Scientific Cat# 31413, RRID:AB_429693

Target Antigen: Human IgG Fc

Host Organism: goat

Clonality: polyclonal secondary

Comments: Applications: ICC/IF (1:500-1:5,000), IHC (1:500-1:5,000), WB (1:10,000-1:200,000)

Antibody Name: Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, HRP

Description: This polyclonal secondary targets Human IgG Fc

Target Organism: human

Defining Citation: [PMID:24260554](#), [PMID:25954273](#)

Antibody ID: AB_429693

Vendor: Thermo Fisher Scientific

Catalog Number: 31413

Record Creation Time: 20250820T030147+0000

Record Last Update: 20250820T150943+0000

Ratings and Alerts

No rating or validation information has been found for Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, HRP.

No alerts have been found for Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, HRP.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Feng Y, et al. (2025) Antibiotic-induced gut microbiome perturbation alters the immune responses to the rabies vaccine. *Cell host & microbe*, 33(5), 705.

Kready K, et al. (2025) A long-lasting prolactin stimulates galactopoiesis in mice. *iScience*, 28(8), 113112.

Slein MD, et al. (2024) Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D. *Cell reports. Medicine*, 5(2), 101417.

Zhao R, et al. (2024) Sustained amphiregulin expression in intermediate alveolar stem cells drives progressive fibrosis. *Cell stem cell*, 31(9), 1344.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. *Cancer immunology research*, 12(4), 491.

Zhang N, et al. (2024) Cell surface RNAs control neutrophil recruitment. *Cell*, 187(4), 846.

Nicolas A, et al. (2023) An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells. *iScience*, 26(1), 105904.

Tauzin A, et al. (2022) A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses. *Cell reports*, 41(4), 111554.

Beaudoin-Bussières G, et al. (2022) A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. *Cell reports*, 38(7), 110368.

Tauzin A, et al. (2022) Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients. *iScience*, 25(9), 104990.

Milligan JC, et al. (2022) Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. *Cell*, 185(6), 995.

Rappazzo CG, et al. (2022) Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein. *Immunity*, 55(9), 1710.

Ilinykh PA, et al. (2020) Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies. *Cell host & microbe*, 27(6), 976.